Real‐world, single‐centre experience of apremilast for the treatment of moderate to severe psoriasis

TH Wong, S Sinclair, B Smith, C Fraser… - Clinical and …, 2017 - academic.oup.com
The introduction of several new therapeutic agents, predominantly biologic therapies, has
transformed the management of moderate and severe psoriasis in recent years. A novel oral …
被引用次数：22 相关文章

[引用][C] Real-world, single-centre experience of apremilast for the treatment of moderate to severe psoriasis.

TH Wong, S Sinclair, B Smith, C Fraser… - Clinical and …, 2017 - europepmc.org
Real-world, single-centre experience of apremilast for the treatment of moderate to severe
psoriasis. - Abstract - Europe PMC Sign in | Create an account https://orcid.org Europe PMC …

[引用][C] Real-world, single-centre experience of apremilast for the treatment of moderate to severe psoriasis

TH Wong, S Sinclair, B Smith, C Fraser… - Clinical and Experimental …, 2017 - cir.nii.ac.jp
Real-world, single-centre experience of apremilast for the treatment of moderate to severe
psoriasis | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索 …

[引用][C] Real‐world, single‐centre experience of apremilast for the treatment of moderate to severe psoriasis

TH Wong, S Sinclair, B Smith, C Fraser… - Clinical and …, 2017 - Wiley Online Library
Conflict of interest: CAM has received speaker honoraria from Galderma, Leo Pharma and
Spirit Healthcare, and has been reimbursed for advisory board attendance by Abbvie …

[引用][C] Real-world, single-centre experience of apremilast for the treatment of moderate to severe psoriasis

TH Wong, S Sinclair, B Smith… - Clinical and …, 2017 - pubmed.ncbi.nlm.nih.gov
Real-world, single-centre experience of apremilast for the treatment of moderate to severe
psoriasis Real-world, single-centre experience of apremilast for the treatment of moderate to …

Real-world, single-centre experience of apremilast for the treatment of moderate to severe psoriasis.

TH Wong, S Sinclair, B Smith… - Clinical & …, 2017 - search.ebscohost.com
The article presents a study conducted on the efficacy of apremilast for the treatment of
moderate to severe psoriasis. Topics discussed include after 16 weeks of treatment half of …